For the Inventor, By the Inventor

Enter assignee name

Plymouth Meeting, PA, United States of America

Vgx Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 18

% Expired Patents = 11.1

CIPO Patents = 6

EPO Patents = 3

Trademarks = 3

Forward Citations = 200

Loading Chart...

Loading Chart...

31 inventors (with patents filed for the assignee):

Ruxandra Draghia-Akli (14 out of 28 patents)

Amir S Khan (5 out of 10 patents)

Douglas R Kern (4 out of 9 patents)

4. Patricia A Brown (3 out of 10 patents)

5. Mathura P Ramanathan (3 out of 14 patents)

6. Robert Hunt Carpenter (3 out of 28 patents)

7. Niranjan Y Sardesai (3 out of 30 patents)

8. Melissa Pope (3 out of 3 patents)

9. William R Wilkinson (1 out of 25 patents)

10. Jian Yan (1 out of 73 patents)

11. Kate Broderick (1 out of 21 patents)

12. Karuppiah Muthumani (1 out of 30 patents)

13. Bernadette Ferraro (1 out of 12 patents)

14. Rodney A Bowling (1 out of 4 patents)

15. Rune Kjeken (1 out of 7 patents)

18 patents: Sort by Forward Citations

1. 10294278 - Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom (2019-05-21),

2. 10232173 - Contactless electropermeabilization electrode and method (2019-03-19),

3. 9452285 - Electroporation devices and methods of using same for electroporation of cells in mammals (2016-09-27),

4. 8962818 - Compositions comprising GHRH and GnRH and methods of using the same (2015-02-24),

5. 8961994 - DNA constructs eliciting immune response against flavivirus and effective adjuvants (2015-02-24),

6. 8927508 - Antibody production elicited by a DNA vaccine delivered by electroporation (2015-01-06),

7. 8835620 - Vaccines against multiple subtypes of dengue virus (2014-09-16),

8. 8563302 - Optimized high yield synthetic plasmids (2013-10-22),

9. 8481504 - Insulin-like growth factor (IGF-I) plasmid-mediated supplementation for therapeutic applications (2013-07-09),

10. 8209006 - Constant current electroporation device and methods of use (2012-06-26),

11. 8188056 - Reducing arthritis and lameness in subjects by growth hormone releasing hormone (GHRH) supplementation (2012-05-29),

12. 8178504 - Gene therapy expression of GHRH for increasing RBC count in subjects (2012-05-15),

13. 8058253 - Growth hormone releasing hormone treatment to decrease cholesterol levels (2011-11-15),

14. 7846720 - Optimized high yield synthetic plasmids (2010-12-07),

15. 7664545 - Electrode assembly for constant-current electroporation and use (2010-02-16),

Company Overview

Vgx Pharmaceuticals, Inc. is a biopharmaceutical company based in Plymouth Meeting, PA, specializing in the development of innovative therapies for various medical conditions. The company focuses on advanced drug delivery systems and gene therapy technologies, aiming to address unmet medical needs through its proprietary platforms. With a commitment to research and development, Vgx Pharmaceuticals is dedicated to improving patient outcomes and enhancing the quality of life through its cutting-edge therapeutic solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

18 Patents

#8 in Plymouth Meeting, PA

#659 in Pennsylvania

#17,980 in US

#34,263 in the World

Plymouth Meeting, PA, United States of America

Vgx Pharmaceuticals, Inc.

Forward Citations = 200

31 inventors:

Ruxandra Draghia-Akli (14 out of 28 patents)

Amir S Khan (5 out of 10 patents)

Douglas R Kern (4 out of 9 patents)

4. Patricia A Brown (3 out of 10 patents)

5. Mathura P Ramanathan (3 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vgx Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/vgx-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…